Skip to content
lifestyle.pspl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
InflaRx N.V.
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
May 4, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
May 2, 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
May 2, 2026
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
May 1, 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
April 30, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026
April 29, 2026
←
Previous Page
1
2